Last 27 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Harmony Biosciences Holdings, Inc.'s quarterly P/E stands at 12.7x, up 19.7% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 11.4% YoY to 7.3x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 12.61 | 12.73 | 24.62 | 7.92 | 11.62 | 10.64 | 10.12 | 12.66 | 37.71 | 12.53 | 17.94 | 13.00 | 15.71 |
| — | +19.7% | +143.3% | -37.4% | -69.2% | -15.1% | -43.6% | -2.7% | +140.1% | -26.3% | +2.9% | +69.1% | -49.7% | |
| P/S Ratio | 2.28 | 1.91 | 2.25 | 1.69 | 2.30 | 2.63 | 2.49 | 3.12 | 2.51 | 3.13 | 2.82 | 3.10 | 3.98 |
| — | -27.3% | -9.5% | -45.9% | -8.3% | -15.9% | -11.8% | +0.7% | -36.9% | -25.4% | -57.3% | -46.4% | -42.6% | |
| P/B Ratio | 2.30 | 1.81 | 2.52 | 1.94 | 2.39 | 2.70 | 3.04 | 3.89 | 3.22 | 3.75 | 4.07 | 4.13 | 4.41 |
| — | -32.9% | -17.0% | -50.2% | -25.9% | -28.2% | -25.3% | -5.7% | -26.8% | -16.8% | -51.7% | -47.6% | -63.4% | |
| P/FCF | 5.68 | 14.83 | 4.36 | 3.72 | 5.82 | 14.34 | 6.67 | 8.24 | 10.34 | 15.53 | 6.21 | 7.88 | 14.50 |
| — | +3.4% | -34.7% | -54.8% | -43.7% | -7.6% | +7.5% | +4.6% | -28.7% | +32.3% | -80.5% | -35.9% | -34.2% | |
| EV / EBITDA | 6.26 | 7.30 | 9.15 | 3.99 | 6.80 | 6.55 | 7.02 | 7.84 | 14.67 | 7.71 | 9.64 | 6.60 | 9.51 |
| — | +11.4% | +30.4% | -49.1% | -53.6% | -15.0% | -27.2% | +18.8% | +54.3% | -24.6% | -38.1% | -82.1% | -49.1% | |
| EV / EBIT | 7.03 | 7.36 | 9.50 | 4.23 | 6.91 | 6.68 | 7.17 | 7.98 | 15.40 | 7.96 | 8.10 | 7.92 | 10.01 |
| — | +10.1% | +32.5% | -47.0% | -55.1% | -16.1% | -11.4% | +0.7% | +53.9% | -27.1% | -53.8% | -85.7% | -54.6% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Harmony Biosciences Holdings, Inc.'s operating margin was 17.3% in Q1 2026, up 1.5 pp QoQ and down 13.1 pp YoY. The trailing four-quarter average of 21.1% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 4.0% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.2% | 79.3% | 71.9% | 75.1% | 81.0% | 82.7% | 73.0% | 77.0% | 81.4% | 82.2% | 74.4% | 79.8% | 81.4% |
| — | -4.0% | -1.5% | -2.5% | -0.5% | +0.6% | -1.9% | -3.6% | +0.0% | -0.4% | -5.9% | -0.7% | -1.2% | |
| Operating Margin | 24.0% | 17.3% | 15.8% | 27.3% | 24.0% | 30.4% | 27.7% | 33.2% | 12.4% | 33.7% | 23.9% | 40.3% | 34.9% |
| — | -43.1% | -42.9% | -17.6% | +94.5% | -9.5% | +16.0% | -17.6% | -64.6% | -0.8% | -35.7% | +296.4% | +12.9% | |
| Net Margin | 18.3% | 15.1% | 9.2% | 21.2% | 19.8% | 24.7% | 24.6% | 24.8% | 6.7% | 24.8% | 15.8% | 24.0% | 25.6% |
| — | -38.8% | -62.5% | -14.3% | +195.8% | -0.5% | +55.6% | +3.2% | -73.8% | +0.2% | -58.2% | -68.0% | +16.2% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 20.8% | 3.6% | 2.6% | 6.3% | 5.3% | 6.6% | 7.9% | 8.1% | 2.2% | 7.8% | 5.6% | 8.0% | 7.4% |
| — | -44.7% | -66.5% | -22.1% | +142.2% | -15.4% | +40.4% | +2.0% | -70.2% | +11.9% | -56.8% | -73.3% | -27.6% | |
| ROA | 14.0% | 2.6% | 1.8% | 4.4% | 3.7% | 4.4% | 5.1% | 5.2% | 1.4% | 4.6% | 3.3% | 5.0% | 4.7% |
| — | -42.4% | -64.7% | -14.9% | +170.5% | -4.1% | +53.3% | +3.2% | -70.8% | +8.9% | -54.5% | -67.3% | -4.3% | |
| ROIC | 42.0% | 6.3% | 8.1% | 13.0% | 8.9% | 10.6% | 10.7% | 11.5% | 4.1% | 10.7% | 8.5% | 13.5% | 9.9% |
| — | -40.3% | -24.3% | +12.7% | +119.0% | -1.4% | +25.5% | -14.7% | -59.0% | +23.5% | -25.5% | +259.4% | -23.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Harmony Biosciences Holdings, Inc.'s Debt/EBITDA ratio is 4.8x, down from 5.2x last quarter — elevated, raising questions about debt serviceability.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.28 | 0.23 | 0.28 | 0.20 | 0.22 | 0.25 | 0.28 | 0.31 | 0.35 | 0.37 | 0.42 | 0.41 | 0.40 |
| — | -7.9% | +0.0% | -34.5% | -36.1% | -34.2% | -34.5% | -25.2% | -12.1% | -13.4% | -11.7% | -25.6% | -48.7% | |
| Debt / EBITDA | 1.02 | 4.77 | 5.21 | 2.38 | 3.20 | 2.85 | 2.94 | 2.74 | 6.90 | 3.32 | 4.23 | 2.83 | 3.66 |
| — | +67.4% | +77.2% | -13.2% | -53.6% | -14.1% | -30.5% | -3.2% | +88.6% | -19.4% | +18.6% | -73.5% | -25.3% | |
| Current Ratio | 3.60 | 3.58 | 3.60 | 3.75 | 3.84 | 3.67 | 3.31 | 3.24 | 3.13 | 3.11 | 2.75 | 4.12 | 4.90 |
| — | -2.4% | +8.7% | +15.9% | +22.7% | +18.1% | +20.1% | -21.4% | -36.1% | -36.5% | -45.7% | +15.7% | -0.2% | |
| Quick Ratio | 3.58 | 3.56 | 3.58 | 3.72 | 3.80 | 3.63 | 3.27 | 3.20 | 3.09 | 3.07 | 2.72 | 4.07 | 4.84 |
| — | -2.1% | +9.5% | +16.5% | +23.2% | +18.3% | +20.1% | -21.5% | -36.3% | -36.7% | -45.8% | +15.6% | +0.0% | |
| Interest Coverage | 15.68 | 13.27 | 12.49 | 18.64 | 14.61 | 15.91 | 14.34 | 15.30 | 5.93 | 12.42 | 11.49 | 8.39 | 8.09 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 27 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HRMY stock.
Harmony Biosciences Holdings, Inc.'s current P/E is 12.6x. The average P/E over the last 4 quarters is 14.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Harmony Biosciences Holdings, Inc.'s current operating margin is 24.0%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Harmony Biosciences Holdings, Inc.'s business trajectory between earnings reports.